VESIcare For Improving OAB Symptoms in Patients Undergoing IGRT of the Prostate (NCT01777217) | Clinical Trial Compass
TerminatedPhase 4
VESIcare For Improving OAB Symptoms in Patients Undergoing IGRT of the Prostate
Stopped: Terminated
United States8 participantsStarted 2013-02
Plain-language summary
The purpose of this study is to determine if Vesicare (Solifenacin succinate) is effective in treating over-active bladder symptoms during radiation therapy of the prostate.
Who can participate
Age range18 Years
SexMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written Informed Consent and privacy language as per HIPAA Authorization for the USA test sites is obtained from subject or legally authorized representative prior to the initiation of this study (including withdrawal of prohibited medication, if applicable)
✓. Subject must be an ambulatory male at least 18 years of age.
✓. Subject has been diagnosed with prostate carcinoma and has elected to undergo external beam radiation therapy.
✓. Subject is willing to complete the American Urology Association Symptom Score (AUASS) Questionnaire.
Exclusion criteria
✕. Subject has undergone a prostatectomy
✕. Subject exhibits symptoms of urinary tract infection.
✕. Subject exhibits severe neurologic damage or has undergone prostatectomy.
✕. Subject diagnosed with OAB and is being treated with medication for alleviation of OAB symptoms within 12 months prior to the Screening Visit.
✕. Subject has evidence of uncontrolled narrow angle glaucoma, urinary or gastric retention, neurogenic bladder; prostatitis, or persistent UTI.
✕. Subject exhibits hypersensitivity to Solifenacin succinate, any ingredients, or other anticholinergic agents.
✕. Subject has undergone treatment with any investigational drug within 30 days prior to screening procedure.
What they're measuring
1
Change From Baseline to End of Study Measured by the American Urology Association Symptom Score Questionnaire (AUASS).